NASDAQ: SUPN

Price:
9.06
Change:
+ 0.25
Day High:
9.09
Day Low:
8.80
Volume:
457,500
4:00 PM ET on Aug 29, 2014
Delayed at least 20 minutes.
Provided by eSignal.

Shareholder Tools

Investor Relations

We are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. Our extensive expertise in product development has been built over the past 20 years: initially as a standalone development organization, then as a U.S. subsidiary of Shire plc and, upon our acquisition of substantially all the assets of Shire Laboratories Inc. in late 2005, as Supernus Pharmaceuticals. In 2013 we launched our two epilepsy products, Oxtellar XR® and Trokendi XR®  We are developing several product candidates in psychiatry to address large market opportunities in attention deficit hyperactivity disorder, or ADHD, including ADHD with impulsive aggression. We market our epilepsy products through our own focused, specialty sale force in the United States. We believe our diversified and broad portfolio of product candidates provides us with multiple opportunities to achieve our goal of becoming a leading specialty pharmaceutical company focused on CNS diseases.

View all »   RSSRecent Releases

Aug 21, 2014
Supernus Announces Paragraph IV ANDA Filing for Trokendi XR(R)

Aug 19, 2014
Supernus to Attend FBR HealthCare Conference in September